MSM: Real Joint Evidence in a Supplement Category Full of Noise

What the osteoarthritis trials actually show

The two most-cited randomized trials both point the same direction. Kim and colleagues (2006) randomized 50 patients with knee OA to MSM 3 g twice daily or placebo for 12 weeks and found significant improvements in WOMAC pain and physical-function scores, though not in stiffness or aggregate symptom scores. Debbi and colleagues (2011) randomized 49 patients to roughly 3.4 g/day and reported significant gains in WOMAC physical function and total score — but, notably, the between-group difference in WOMAC pain did not reach statistical significance, and the authors were explicit that the improvements were "small and it is yet to be determined if they are of clinical significance."

That caution matters because the higher-level evidence is mixed. A 2011 meta-analysis by Brien and colleagues pooled the eligible DMSO and MSM trials (326 patients) and concluded that current evidence does not show a clinically meaningful reduction in osteoarthritis pain, citing short dosing periods and inconsistent results. A larger 2017 systematic review and meta-analysis of 20 supplements for osteoarthritis (Liu and colleagues, in the British Journal of Sports Medicine) placed MSM among the agents with a statistically significant but clinically unclear effect on pain — the same tier as glucosamine and chondroitin. So MSM is not a dud, but it sits squarely in the "small, possibly real, not transformative" category.

Recovery from exercise

MSM is also marketed to athletes for muscle soreness and recovery, and a handful of small trials have tested this. In a double-blind trial of 22 half-marathon runners, MSM 3 g/day for three weeks before and after the race did not significantly lower oxidative-stress or muscle-damage markers, but the MSM group did show clinically meaningful (if not statistically significant) reductions in muscle and joint pain (Withee and colleagues, 2017). A small pilot study in resistance-trained men found that 3 g/day tended to reduce muscle soreness and fatigue versus 1.5 g/day, with improved antioxidant capacity (Kalman and colleagues, 2012). These are underpowered proof-of-concept studies; the effect sizes are small, and anyone reporting dramatic gains is likely experiencing a large placebo component.

Mechanism

MSM is a sulfur donor that participates in methylation reactions and appears to dampen pro-inflammatory signaling — preclinical work links it to reduced NF-κB activation and lower TNF-α and IL-6 — and it may support glutathione-based antioxidant defenses. Like other sulfur-containing compounds such as NAC and taurine, its action is best described as broad and low-level rather than a single precise drug-like mechanism. That diffuse pharmacology is consistent with the modest, hard-to-pin-down clinical effects.

Combining with glucosamine and chondroitin

Combination products dominate the joint-supplement shelf. The most useful head-to-head data come from Usha and Naidu (2004), who randomized 118 knee-OA patients to glucosamine, MSM, the combination, or placebo for 12 weeks. All three active arms beat placebo, and the combination produced a larger and faster reduction in pain and swelling than either agent alone. The trial was small and industry-relevant, so treat it as suggestive: MSM appears to contribute independently, and combining it with glucosamine and chondroitin may add a little, but no single ingredient here is a heavy hitter. If budget is the constraint, any one of them alone delivers a roughly similar, modest effect.

Safety and dose

The trial doses cluster at 3–6 g/day, split into two or three doses, with onset of any benefit typically at two to four weeks. MSM was well tolerated across these studies; reported side effects are limited to mild gastrointestinal upset, occasional headache, and a faint sulphur aftertaste at higher doses. No clinically important drug interactions have been established, and tolerability held up over the multi-week trial periods. As with any supplement taken for a chronic joint condition, it is an adjunct — not a replacement for weight management, exercise, or appropriate pharmacologic care.

Bottom line

MSM is one of the better-tolerated joint supplements and has genuine, if small, randomized evidence behind it for knee osteoarthritis. The catch is that the effect on pain is inconsistent across trials and meta-analyses, and the studies are uniformly small and short. A 4–6 week trial at 3–6 g/day is a low-risk thing to try; if you notice nothing by then, you are unlikely to be missing much.